United Laboratories International (HKG:3933) said its wholly owned unit, Zhuhai United Laboratories, has completed a Phase 2 clinical trial in China for TUL01101 tablets, a Class 1 new drug for treating moderate-to-severe atopic dermatitis, according to a Monday bourse filing.

Shares of the firm were up nearly 3% in Tuesday morning trade.

The multicenter trial enrolled 201 adult patients and tested three dose groups over 12 weeks.

All doses showed significant efficacy, with Eczema Area and Severity Index (EASI) score reductions of up to 87.9% and an EASI-75 response rate as high as 84%, according to the filing.

The drug also demonstrated a favorable safety profile, with most adverse events being mild to moderate.

Following the positive results, the company has begun discussions with regulators and is initiating a Phase 3 clinical trial in China.